Research Triangle Park, NC (Nov. 13)-Eisai Inc. broke ground here for a new pharmaceutical production and formulation research and development facility for parenteral oncology drugs.
Research Triangle Park, NC (Nov. 13)-Eisai Inc. (Teaneck, NJ, www.eisai.com) broke ground here for a new pharmaceutical production and formulation research and development facility for parenteral oncology drugs.
Eisai will invest $90 million in the 65,000-ft2 facility, which will encompass aseptic processing suites, laboratories, and other support functions. In addition, a separate $15-million central utilities building is planned to supply power, steam, chilled water, and compressed air to existing and new operations. Facility completion is expected in three years with operations beginning in 2009.
The new facility will complement the company’s existing 190,000-ft2 structure. That facility manufactures “Aricept” (donepezil hydrochloride) and “Aciphex” (rabeprazole sodium) tablets and also houses formulation research and development and manufacturing of compounds for use in clinical trials.
Eisai has several oncology drugs in development and recently acquired four oncology-related products from Ligand Pharmaceuticals (San Diego, CA, www.ligand.com).
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.